PCSK9 Recombinant antibody, PBS Only (Capture)

PCSK9 Uni-rAbTM Recombinant Antibody for WB, Cytometric bead array, Sandwich ELISA, Indirect ELISA, Sample test

Host / Isotype

Rabbit / IgG

Reactivity

human

Applications

WB, Cytometric bead array, Sandwich ELISA, Indirect ELISA, Sample test

Conjugate

Unconjugated

CloneNo.

241395G1

Cat no : 84172-4-PBS

Synonyms

NARC 1, LDLCQ1, HCHOLA3, FH3, EC:3.4.21.-



Product Information

84172-4-PBS targets PCSK9 as part of a matched antibody pair:

MP01071-3: 84172-4-PBS capture and 84172-3-PBS detection (validated in Cytometric bead array)

MP01071-4: 84172-4-PBS capture and 84172-6-PBS detection (validated in Sandwich ELISA)

Unconjugated rabbit recombinant monoclonal antibody in PBS only (BSA and azide free) storage buffer at a concentration of 1 mg/mL, ready for conjugation. Created using Proteintech’s proprietary in-house recombinant technology. Recombinant production enables unrivalled batch-to-batch consistency, easy scale-up, and future security of supply.

This conjugation ready format makes antibodies ideal for use in many applications including: ELISAs, multiplex assays requiring matched pairs, mass cytometry, and multiplex imaging applications.Antibody use should be optimized by the end user for each application and assay.

Tested Reactivity human
Host / Isotype Rabbit / IgG
Class Recombinant
Type Antibody
Immunogen Fusion Protein
Full Name proprotein convertase subtilisin/kexin type 9
Calculated Molecular Weight74 kDa
Observed Molecular Weight 72-78 kDa, 62 kDa
GenBank Accession NumberNM_174936.4
Gene Symbol PCSK9
Gene ID (NCBI) 255738
Conjugate Unconjugated
Form Liquid
Purification MethodProtein A purification
Storage Buffer PBS Only
Storage ConditionsStore at -80°C.

Background Information

Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a crucial protein governing the circulating levels of low density lipoprotein-cholesterol (LDL-C), by virtue of its pivotal role in the degradation of the LDL receptor (LDLR). PCSK9 is expressed in the kidney and lung. It is synthesized as a 72 kDa immature precursor that undergoes autocatalytic cleavage in the endoplasmic reticulum to generate a 63 kDa mature protein. The cleaved N-terminal fragment remains associated with the mature protein and is necessary for its secretion, allowing it to circulate in the blood. The ability of PCSK9 to regulate a diverse group of cell-surface proteins hinted that it might also be able to influence additional membrane proteins that are important in anti-tumour immune responses. Targeting PCSK9 to treat cancer is also attractive because two neutralizing antibodies against it, evolocumab and alirocumab, have already been approved for human clinical use to lower cholesterol levels. (PMID: 30522786, PMID: 22493497)